2026-04-27 – Press Releases – www.prnewswire.com
– 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. – Topline data from the Phase II study are expected in the third quarter of 2026. HONG KONG, April 27,…
